Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806186 | 0.96 | SUCNR1 (0.46) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL16383864 | 0.87 | SUCNR1 (0.45) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL16383769 | 0.87 | CA1 (0.57) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL17919114 | 0.82 | MAPK1 (0.57) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL16383753 | 0.82 | MAPK1 (0.57) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL16344311 | 0.81 | CA1 (0.57) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL17809668 | 0.81 | CA1 (0.55) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL27301122 | 0.81 | ITGB3 (0.53) | ITGB3ITGA2B | |
| SCHEMBL17919110 | 0.81 | CA1 (0.55) | SUCNR1CA1CA2CA12CA9 | |
| SCHEMBL16383779 | 0.81 | CA1 (0.57) | SUCNR1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656972-B2 | Compounds for treatment of cystic fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, ELANE, OTC | SUCNR1 1000/4885CA1 4834/4885CA2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.